The pharmaceutical giant reported net income of $1.82 billion, or $1.02 per share, a sharp recovery from the $22 million loss recorded during the same period last year. On an adjusted basis, AbbVie earned $2.71 per share, surpassing the $2.65 average estimate from analysts polled by FactSet. Total net revenue climbed 10%, driven largely by an 18% surge in both the immunology and neuroscience divisions.
In section Market Quotes
AbbVie Exceeds Forecasts as Immunology Growth Offsets Humira Slump
AbbVie Inc. outperformed Wall Street expectations in the fourth quarter, posting $16.62 billion in revenue as its newer immunology and neuroscience treatments cushioned the impact of biosimilar competition for its former top-selling drug, Humira.
Strengthening the Immunology Pipeline
The company’s strategic pivot away from Humira—which saw a 26% decline in sales due to low-cost competitors—appears to be gaining momentum. Growth was primarily fueled by the blockbuster success of Skyrizi and Rinvoq, which saw revenue jumps of 32.5% and 29.5%, respectively. These two therapies now anchor a portfolio that generated $8.63 billion in quarterly revenue, while the neuroscience segment contributed another $2.96 billion to the top line.Looking ahead, AbbVie issued optimistic long-term guidance that exceeded market projections. The company expects adjusted earnings for 2026 to fall between $14.37 and $14.57 per share. This forecast sits comfortably above the $14.27 per share currently anticipated by Wall Street analysts, signaling confidence in the sustained trajectory of its newer clinical offerings.
Comments (0)
No comments yet. Be the first!